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INTRODUCTION 25 
Chronic kidney disease (CKD) is a commonly recognised heterogeneous disease syndrome in cats, 26 
with previous studies estimating a prevalence of 1.7% to 3.6% in cats attending primary-care 27 
practice in the UK 1,2. Prevalence increases with age, with up to 80% of cats aged over 15 years 28 
estimated to have CKD in some studies 3–5. Kidney disease has also been reported as the most 29 
common cause of death in cats over 5 years of ages in the UK, with almost 1 in 7 animals dying of 30 
this condition6. Previously reported median survival time estimates ranged from 21 days to 1151 31 
days depending on severity of renal dysfunction at diagnosis 7–9. 32 
It has previously been reported that CKD does not become clinically apparent until around 75% of 33 
the renal function has been lost 10. Though as the condition progresses, considerable morbidity has 34 
been reported, with cats experiencing a range of clinical signs as the disease progresses. The most 35 
commonly described clinical signs were polydipsia, weight loss, anorexia, polyuria, depression, and 36 
vomiting 8,11,12, with anorexia, weight loss and depression all reported to negatively impact on the 37 
quality of life of the cat 13. 38 
Previously reported risk factors for CKD diagnosis include age 8,11,14, sex 15,16, breed 11,15, 39 
hyperthyroidism 17,18, feline leukaemia virus (FeLV) 19,20 and feline immunodeficiency virus (FIV) 21,22. 40 
Vaccination 23 and incomplete recovery from acute kidney injury 24 have additionally been 41 
hypothesised as other potential risk factors. Useful prognostic indicators following diagnosis include 42 
proteinuria 25–27, the feeding of a low protein, low phosphate diet 9,28, anaemia 25,27,29 and serum 43 
phosphate levels 25,27,29. No single variable has been identified that reliably predicts survival following 44 
diagnosis of CKD. This may be due to the heterogeneous nature of CKD in cats and the variable rates 45 
of progression observed 27.  46 
Clinically apparent CKD causes considerable morbidity and mortality in cats. Additionally, up to 15% 47 
of apparently healthy cats aged 10 years or older are found to have undiagnosed CKD at a routine 48 
health check 30,31, suggesting that CKD may result in morbidity to a substantial proportion of the 49 
geriatric cat population. Previous research on risk factors for CKD diagnosis and survival following 50 
diagnosis of CKD has been limited mainly to referral populations, prospective research following 51 
standard protocols focussing on one region (London) and questionnaire based studies, with little 52 
work undertaken using general primary-care data. This may reduce the generalisability of the results 53 
to the wider cat population32. This study aimed to estimate prevalence and risk factors for CKD 54 
diagnosed in cats attending VetCompass™ practices in the UK, to document the current standard of 55 
care applied in these practices and to evaluate survival following CKD diagnosis. By comparison with 56 
published expert recommendations (guidelines), these data should assist primary practitioners 57 
identify ways in which diagnosis and management of feline CKD could be improved.  58 
MATERIALS AND METHODS 59 
Ethics approval was provided by the Royal Veterinary College Clinical Research Ethical Review Board 60 
(URN M2015 0050). 61 
Data collection and management 62 
VetCompass™ collects and collates anonymised electronic patient records (EPR) from enrolled 63 
primary-care veterinary practices in the UK. Patient demographic (species, breed, date of birth, sex, 64 
neutering status, bodyweight) and clinical data (free clinical text, VeNom 33 diagnosis terms and 65 
treatment fields) are uploaded for use in research studies1,34. 66 
A stratified prevalence study derived from the cohort of cats attending 244 participating 67 
VetCompass™ practices from 1st January 2012 to 31st December 2013 was used to estimate the 68 
two-year period prevalence 35. A frequency matched case control study, nested within the study 69 
cohort, was used to investigate risk factors for diagnosis of CKD and a retrospective cohort study was 70 
used to explore survival following CKD diagnosis. The sampling protocol for the three studies is 71 
illustrated in Figure 1. Potential cases of CKD were identified by searching the EPR for VeNom 72 
diagnosis codes (renal failure, renal disorder, renal disease, chronic renal failure, renal insufficiency), 73 
treatment (KD, RCW feline renal, renal food, renalzin, ipakitine, alucap, semintra, tumil K, renal 74 
profile, UPC) and free text clinical terms (CKD, CRD, CRF, chronic renal/kidney 75 
failure/disease/insufficiency, kidney disease, renal disease, iris stage). The results from all searches 76 
were merged and duplicates removed. A random sample of 20% of potential cases was selected to 77 
review in detail the EPRs manually. The case definition required a diagnosis of CKD (or synonym) 78 
recorded within the EPR, or a diagnosis of kidney disease (or synonym) within the EPR with evidence 79 
of chronicity of disease, with chronicity defined as the presence of clinical signs or azotaemia for ≥3 80 
months. ‘Pre-existing cases’ were those first diagnosed prior to the study period and ‘incident cases’ 81 
were those first diagnosed during the study period. Controls were identified by examining EPR 82 
records of a random sample of cats not identified as potential cases in the EPR CKD searches. 83 
Controls were required to have not had CKD suspected at any time within the EPR. Controls selected 84 
that were hyperthyroid needed to have been non-azotaemic when total T4 levels were less than 85 
40nmol/l 36 to be included in the study. Cases and controls were frequency matched by age (< 9 86 
years and ≥ 9 years) to control for the effect of age.   87 
Demographic data were extracted automatically from the database, and further clinical data were 88 
extracted manually from the EPR (date of diagnosis, death, reason for presentation at diagnosis, 89 
clinical signs and physical exam results, laboratory results, imaging results, blood pressure 90 
measurement, vaccination history, historical exposure to potential nephrotoxic drugs and toxins, 91 
treatments prescribed and co-morbidities). Data were exported to Microsoft Excel 13 for cleaning 92 
and then further exported to Stata 11 (StataCorp LP, College Station, TX) for statistical analysis. 93 
Sample size calculations indicated that at least 290 cases and 290 controls would be required to be 94 
sampled to detect an odds ratio of 2 or greater for a risk factor present in 10% of controls, assuming 95 
80% power and 95% confidence 37 96 
Medians and interquartile ranges (IQR) were calculated for continuous variables. Age was 97 
categorised as < 9 years or ≥ 9 years. Bodyweight was categorised into quintiles and also maintained 98 
as a continuous variable. Breed was categorised into crossbred and purebred, with purebred being a 99 
recorded breed name recognised by International Cat Care 38. Reason for presentation at CKD 100 
diagnosis was categorised as clinical signs, geriatric health check (apparently healthy cats aged  ≥ 7 101 
years presented for a health check) and monitoring of pre-existing disease. Serum creatinine and 102 
serum phosphate at diagnosis were categorised based on IRIS guidelines 39 and maintained as 103 
continuous variables. Vaccination was categorised as annual, kitten only or non-annual and no 104 
recorded vaccination in the full EPR. Non-steroidal anti-inflammatory drug (NSAID) use was 105 
categorised into one-off treatment, repeated one-off treatment and long term treatment recorded 106 
in the full EPR. Days since last anaesthetic was categorised into 0 – 179 days, 180 – 364 days and no 107 
anaesthetic recorded in 365 days prior to CKD diagnosis.  108 
Statistical Analysis 109 
The prevalence of CKD was estimated from the cohort of cats attending VetCompass™ practices 110 
during the study period. A stratified analysis was used to describe the incidence risk and prevalence 111 
of CKD in the VetCompass™ cat population, with the estimates adjusted for the random sampling of 112 
20% of potential CKD cases (Fig. 1) 35. Stratum 1 contained the cats that had been identified with the 113 
search terms and had their EPR read in detail and had a confirmed case/ non-case status. Stratum 2 114 
contained all the cats that were not identified with the search terms, and were assumed to be non-115 
cases. A probability weighting was ascribed to each stratum (1/the proportion of the group that had 116 
a confirmed case or non-case status) to account for the different proportions of all cats included 40. 117 
All ‘pre-existing’ and ‘incident’ cases were included in prevalence estimates. 118 
In the case-control study all incident cases were included in the analysis and compared to frequency 119 
age-matched controls. Multivariable logistic regression was used to identify risk factors associated 120 
with CKD diagnosis. Cats that had no age recorded were removed from the analysis. Variables that 121 
were broadly associated with diagnosis of CKD (p < 0.2) in the univariable analysis were carried 122 
forward to the multivariable model. Age was forced into the model to control for the frequency 123 
matched sampling strategy. Model fit was assessed using the Hosmer-Lemeshow test 41 and 124 
predictive ability was assessed by examining the area under the ROC curve 42. The model was 125 
adjusted for veterinary group attended as a confounder by inclusion as a variable in the final model. 126 
Statistical significance was set at the 5% level. 127 
All incident cases identified had their clinical notes followed until 31st December 2015. Cats with one 128 
day or more follow up were included in the survival analysis. Median survival time and mortality 129 
rates were estimated. Multivariable Cox proportional hazards modelling was used to investigate risk 130 
factors associated with survival following CKD diagnosis. Variables broadly associated with survival at 131 
the univariable level (p < 0.2) were carried forward to the multivariable model assessment. 132 
Proportionality of hazards was confirmed by assessing the Schoenfeld residuals and the Kaplan-133 
Meier curve. Model fit was assessed by examining the Cox-Snell residuals and predictive ability of 134 
the model was assessed using Harrell’s C concordance statistic 42. The model was adjusted for 135 
veterinary group attended as a confounder by inclusion as a variable in the final model. Statistical 136 
significance was set at the 5% level. 137 
RESULTS 138 
The denominator population included 353,448 cats attending 244 VetCompass™ clinics during the 139 
study period. EPR searches identified 11,836 potential cases, of which 2,368 (20%) were reviewed in 140 
detail and 625 were classified as incident and 336 pre-existing cases. Overall CKD prevalence was 141 
estimated at 1.2% (95% confidence interval (CI) 1.1% - 1.3%). Prevalence increased with age: 0.1% 142 
(95% CI 0.1% - 0.2%) in cats < 9 years and 3.6% (95% CI 3.3% - 3.8%) in cats aged  ≥ 9 years (Table 1). 143 
CKD prevalence by breed was highest in Burmese cats (5%, see Table 1). 144 
 145 
 146 
 147 
Descriptive statistics 148 
Sex was recorded in 98.3% of cats, neuter status in 72.0% of cats and bodyweight in 43.8% of cats. 149 
Age was not recorded in 8 cases and 8 controls. Median age at diagnosis of CKD was 14.8 years (IQR 150 
12.1 – 16.7). 151 
Cats were most commonly diagnosed with CKD following presentation to the veterinary surgeon due 152 
to clinical signs compatible with CKD (66.6%; 416). Diagnosis followed a geriatric health or pre-153 
anaesthetic check in only 10.6% (66) and 7.0% (44) of cases respectively. Weight loss (49.9%; 311), 154 
polydipsia (38.6%; 241) and polyuria (24.5%; 153) were the most frequently reported clinical signs. 155 
At diagnosis, over half of cats (56.6%; 354) had two or more compatible clinical signs recorded, and 156 
24.8% (155) cats had no clinical signs recorded. Diagnosis was confirmed using combined 157 
biochemistry and urine analysis in 52.6% (329) of cats, with 33.9% (212) confirmed with 158 
biochemistry, 3.5% (21) confirmed with urinalysis and 10.1% (63) diagnosed following clinical 159 
examination alone. At diagnosis, 14.4% (90) had urine protein: creatinine ratio (UPC) performed and 160 
11.4% (71) had imaging. IRIS staging39 was recorded in the EPR of 19.8% (124), with 22.6% (28) in 161 
stage one, 46.8% (58) in stage two, 26.3% (74) in stage three and 14.6% (41) in stage four. Serum 162 
creatinine was recorded in the EPR of 45.0% (281). When categorised by serum creatinine 163 
concentration, 5.3% (15) were in IRIS stage one, 53.7% (151) in stage two, 26.3% (74) in stage three 164 
and 14.6% (41) in stage four at diagnosis. During monitoring, repeated biochemistry was carried out 165 
in 32.6% (204) of cats and blood pressure measured in 25.6% (160). Just over half (51.2%; 83) of 166 
those CKD cases where blood pressure was measured were co-morbidly diagnosed with 167 
hypertension. 168 
The most common treatment prescribed to cats diagnosed with CKD was a proprietary renal diet 169 
(63.2%; 395) (Table 2). Just over a fifth of cats (22.8%; 142) had no recorded treatment for CKD, with 170 
over half of these (54.9%; 78) being euthanised within 7 days of CKD diagnosis. 171 
Risk factor analysis 172 
The following variables were found to be broadly associated (p < 0.2) with incident CKD diagnosis 173 
and carried forward to the multivariable analysis: bodyweight, breed, heart auscultation 174 
abnormality, presence of goitre, vaccination, NSAID treatment, days since previous anaesthetic, 175 
hyperthyroidism, arthritis, cystitis, and hepatopathy (all diagnosed prior to CKD). 176 
Cats with no age recorded were excluded from multivariable analysis (8 cases and 8 controls). Table 177 
3 reports the risk factors associated with diagnosis of CKD in the multivariable analysis. Hyperthyroid 178 
cats, purebred cats, the absence of a recorded goitre, the presence of a heart auscultation 179 
abnormality, long term NSAID treatment, no cardiomyopathy diagnosis, no anaesthetic within one 180 
year of diagnosis and a bodyweight < 3.5kg at diagnosis were all associated with increased risk of 181 
CKD diagnosis (Table 3). The model had good fit (Hosmer-Lemeshow p=0.46) and good predictive 182 
ability (area under the ROC curve 0.81).  183 
Survival analysis 184 
Three hundred and eighty (60.8%) cats had death recorded in the EPR during the follow up to the 185 
end of 2015; with 90.3% (343) of these cats being euthanised. The most frequently recorded reason 186 
for euthanasia included CKD (37.9%; 144) and poor quality of life (22.6%; 86). A third (35.8%; 224) of 187 
cats were lost to follow up. Ninety two cats were not seen by a vet following first diagnosis of CKD, 188 
most of which (82.6%; 76) were euthanised at diagnosis. Of these cats, 40.8% (31) had biochemistry 189 
performed. Of the 15 cats with serum creatinine concentration recorded in their EPR, 66.7% (10) 190 
were in IRIS stage 4 CKD.  191 
All-cause mortality rate was calculated as 8.1 deaths per 10.0 CKD cat years at risk (95% CI 7.3 – 9.0). 192 
The 92 cats that were not seen after diagnosis were excluded from further analysis as, from a clinical 193 
perspective, they would not aid any further understanding of prediction of disease progression or 194 
treatment effectiveness.  195 
Median survival time in cats with at least one day follow up was 388 days following diagnosis of CKD 196 
(IQR 88  – 1042 days) (Fig. 2).  The following variables were broadly associated (p < 0.2) with survival 197 
of at least one day following CKD diagnosis at the univariable level: neuter status, breed, 198 
bodyweight, reason for presentation, method of diagnosis, heart auscultation, blood pressure, IRIS 199 
stage at diagnosis, serum phosphate at diagnosis, UPC at diagnosis, treatments used (renal diet, 200 
phosphate binders, potassium supplementation, amlodipine, anabolic steroids, IVFT) , and diagnosis 201 
of; periodontal disease, cystitis, cardiomyopathy, hepatopathy, constipation and diabetes mellitus. 202 
Table 4 details the associations identified with survival of at least one day following CKD diagnosis in 203 
the multivariable Cox proportional hazards model. Serum phosphate at diagnosis, UPC at diagnosis, 204 
breed, proprietary diet prescription, IVFT, diagnosis of constipation, body-weight, phosphate binder 205 
prescription and cystitis diagnosis were all associated with survival. An interaction with time was 206 
identified with the association between serum phosphate at diagnosis and survival. The association 207 
of serum phosphate with survival was only identified in the first 400 days following diagnosis of CKD. 208 
Proportionality of hazards was met (Scaled schoenfeld residuals p=0.22) and the model had good 209 
predictive ability (Harrell’s C = 0.85). 210 
DISCUSSION 211 
This study is the largest to date investigating the prevalence of, and risk factors for, CKD diagnosis 212 
and survival following diagnosis in cats attending primary-care practices in the UK. Prevalence of CKD 213 
in cats attending VetCompass™ practices was estimated as 1.2% (95% CI 1.1% - 1.3%) increasing to 214 
3.6% (95% CI 3.3% - 3.8%) in cats aged ≥ 9 years. The large size of the study population suggests that 215 
this prevalence value is likely to be reasonably generalizable to the UK primary-practice attending 216 
cat population. The overall prevalence was 6 times higher than the prevalence previously reported in 217 
dogs from the same database, and the median survival time following diagnosis in cats was found to 218 
be 1.7 times that in dogs, suggesting that CKD results in a greater burden of disease in cats than dogs 219 
in primary-care practice due to both higher prevalence and duration 34. 220 
In the current study, most cats (66%) were diagnosed with CKD once clinical signs were present, with 221 
many cats showing two or more clinical signs at diagnosis. It has previously been reported that 222 
clinical signs of CKD do not occur until at least 75% of kidney function has been lost 10. This suggests 223 
that CKD is underdiagnosed in this population, as those cats with sub-clinical disease may be missed. 224 
This conclusion is supported by the limited number of diagnoses made during geriatric health 225 
checks, despite previous evidence that up to 15% of apparently healthy geriatric cats have evidence 226 
of CKD after biochemistry and urinalysis 31 and up to 30% of geriatric cats develop azotaemia within 227 
12 months 14,23. The limited proportion of cats diagnosed following a health check suggests that 228 
these are not carried out routinely, indicating there may be many older cats that have undiagnosed 229 
subclinical CKD. This could impact on morbidity and cause a reduction in quality of life associated 230 
with CKD, as earlier diagnosis allows for early implementation of treatments that can slow 231 
progression of disease, limiting development of clinical signs 43.  232 
Monitoring of cats diagnosed with CKD was limited in the current study, with a minority of cats 233 
receiving repeated biochemistry tests, UPC analyses or BP measurements. This is consistent with 234 
findings from a study on monitoring of hyperthyroidism in cats in the UK and a questionnaire 235 
response from owners of cats with CKD 12,44 , despite recommendations to monitor azotaemia, BP 236 
and UPC following CKD diagnosis 39,45. Cats with CKD have been found to have 5 times the risk of 237 
developing hypertension in comparison to cats without CKD 46. It is important to identify 238 
hypertension early to instigate treatment to reduce the risk of target organ damage and its 239 
associated morbidity 47. The limited use of blood pressure measurement indicates that this group of 240 
CKD cats may be at increased morbidity risk from hypertension secondary to CKD. It was not possible 241 
to extract information from the EPR on whether the decision to not perform these investigations 242 
was owner or veterinary dependent, or both. Further study into the decision-making process would 243 
aid targeted education for improved monitoring of CKD. 244 
In the current study, risk factors associated with CKD diagnosis were similar to those previously 245 
identified in other populations, with purebred status11,15 and hyperthyroid status18,48 found to be 246 
associated with CKD diagnosis. The current study is the first to identify long-term NSAID therapy as a 247 
risk factor for CKD. A possible explanation for this is chronic low-level nephrotoxicity causing kidney 248 
injury that leads to CKD 49,50. It is also possible that cats on long-term NSAID therapy represents a 249 
form of diagnostic bias because these cats are more likely to receive blood tests than cats not 250 
receiving therapy. The protective association found in the current study between a recent 251 
anaesthetic and CKD diagnosis is inconsistent with previous research 15. It is plausible that this 252 
association is a form of reverse causality whereby veterinary surgeons opt to avoid anaesthesia on 253 
cats they consider to be at risk of CKD. The association identified between low bodyweight and CKD 254 
diagnosis is likely to indicate reverse causality, as cats diagnosed with CKD are likely to have lost 255 
weight in the months leading up to diagnosis8. 256 
Vaccination 23, periodontal disease 15,23 and cystitis 15 have previously been reported as risk factors 257 
for CKD diagnosis, but were not identified as such in the current study. Differences in study design, 258 
study population and methods of data collection and recording are likely to explain why these 259 
previously identified risk factors for CKD were not identified by the present study. 260 
Similarly to the risk factor analysis, a number of variables found to be associated with survival have 261 
been previously identified, including serum phosphate concentration 7,27, proteinuria 25,26 and the 262 
use of a proprietary renal diet 9,28,43. Serum phosphate concentration was only predictive in the first 263 
400 days following diagnosis. This is logical given the mainstay of CKD treatment is reduction of 264 
phosphate through proprietary diets and oral phosphate binders, so a single measurement of serum 265 
phosphate concentration at diagnosis of CKD is unlikely to be predictive of survival once is 266 
successfully implemented.  267 
The other variables associated with survival were likely related to disease severity at diagnosis 268 
(bodyweight 8,  IVFT 8 and constipation 51,52), or were related to owner management of the cat. It is 269 
possible that owners of purebred cats are more likely to pursue investigations and treatments for 270 
their cats in comparison to owners of crossbred cats, or that purebred cats may be more likely to be 271 
insured, although insurance status has not been shown to be associated with longevity in previous 272 
studies 6. As cystitis is usually a chronic disease in cats, cystitis cases may have more frequent 273 
veterinary visits and therefore receive improved veterinary care compared to cats that visited less 274 
frequently. 275 
There were limitations to the present study. The data were not collected for research purposes, so 276 
information may have been inconsistently recorded in all EPRs (i.e. high missing-ness). This was 277 
particularly evident for blood test results and possibly resulting in serum creatinine levels and PCV 278 
not being associated with survival, despite being previously identified as strong risk factors 25,26,29. To 279 
ensure adequate power, cats with missing data for these variables were retained in the analyses. 280 
The case definition relied on the veterinary surgeons to correctly diagnose CKD rather than a strict 281 
definition based on biochemical markers. It is possible that some misclassification of cases could 282 
have occurred. Insurance data were not available for this study. Insurance status has been identified 283 
as a risk factor for diagnosis of other conditions, so may be a confounder for some of the variables in 284 
the final models 34,53.  As a third of cats were lost to follow up, it is possible that there was bias 285 
within the survival estimates. Some of the cats lost to follow up may have died at home or were 286 
euthanised at another practice, although it is common for owners to notify veterinary practices of 287 
death as most practices send notifications for routine check-ups required. 288 
In conclusion, CKD appears to be diagnosed relatively late in the course of the disease in primary 289 
care practice. Most cats are diagnosed once clinical signs are present, while monitoring following 290 
CKD diagnosis is limited. Increased uptake of routine screening of higher risk cats using urinalysis and 291 
biochemistry may identify cats with pre-clinical CKD before clinical signs appear, allowing earlier 292 
intervention and a reduction in morbidity and mortality associated with CKD by the application of 293 
treatments aimed at slowing progression of the disease. Improved BP monitoring could aid 294 
reduction in co-morbidity associated with hypertension and target organ damage. These findings can 295 
aid the improved management, health and welfare of CKD cats in primary-care practice. 296 
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TABLES AND FIGURES 458 
Figure 1: Flow chart showing case and control selection and inclusion in each study.  459 
EPR: Electronic Patient Record 460 
 461 
  462 
Figure 2: Kaplan-Meier survival curve of all cats diagnosed with CKD in UK primary-care practice from 463 
1/1/2012 – 31/12/2013 with at least 1 day of follow up (n=533) 464 
 465 
 466 
 467 
  468 
Table 1: Prevalence of chronic kidney disease in cats attending primary-care practice in the UK from 469 
1st January 2012 to 31st December 2013 470 
  Denominator Cases Prevalence1 95% Confidence 
interval 
Overall 
Age (years) 
 
 
 
 
 
Breed 
 
 
 
 
 
 
 
 
 
0 - < 4.5 
4.5 - < 9 
9 - < 13.5 
13.5 - < 18 
18 - < 22.5 
22.5 - < 27 
Crossbreed 
Burmese 
British Shorthair 
Bengal 
Persian 
Siamese 
Main Coon 
Other pedigree 
Unknown 
353448 
118136 
67842 
45597 
30586 
7672 
317 
341791 
3173 
7057 
4167 
4202 
2990 
2428 
11531 
3081 
961 
17 
58 
212 
478 
186 
1 
800 
44 
14 
3 
25 
22 
4 
38 
11 
1.2% 
0.1% 
0.4% 
1.9% 
4.7% 
6.5% 
1.1% 
1.1% 
5.0% 
0.9% 
0.3% 
2.3% 
2.9% 
0.8% 
1.5% 
1.6% 
1.1% - 1.3% 
0.02% - 0.07% 
0.3% - 0.5% 
1.6% - 2.1% 
4.3% - 5.1% 
5.6% - 7.4% 
0% - 3.2% 
1.05% - 1.20% 
3.54% - 6.35% 
0.42% - 1.33% 
0% - 0.73% 
1.44% - 3.24% 
1.72% - 4.08% 
0.02% - 1.48% 
1.00% - 1.92% 
0.66% - 2.51% 
¹ Calculated using stratified analysis 471 
  472 
Table 2: Treatments prescribed to 549 cats attending primary-care practice in the UK and diagnosed 473 
with chronic kidney disease and not euthanased at diagnosis. 474 
 475 
 476 
 477 
 478 
 479 
 480 
 481 
 482 
 483 
 484 
  485 
Treatment N (%) 
Proprietary renal diet 
Antiproteinuric treatment 
 
 
 
Intravenous fluid therapy 
Oral Phosphate binder 
Amlodipine 
Anabolic steroid 
Multivitamin injections 
Subcutaneous fluid therapy 
Potassium supplementation 
Anti-nausea medication 
 
Benazepril 
Telmisartan 
Ramipril 
Imidapril 
 
 
 
 
 
 
 
H2 blocker 
Maropitant 
Metoclopramide 
395 (63.2%) 
221 (35.4%) 
23 (3.7%) 
2 (0.3%) 
1 (0.2%) 
121 (19.4%) 
91 (14.6%) 
66 (10.6%) 
61 (9.8%) 
61 (9.8%) 
19 (3.0%) 
10 (1.6%) 
29 (4.6%) 
20 (3.2%) 
4 (0.6%) 
Table 3: Multivariable logistic regression analysis for diagnosis of chronic kidney disease in cats 486 
attending primary-care practice in the UK from 1st January 2012 to 31st December 2013. Adjusted for 487 
vet group effects. 488 
 489 
1NSAID: Non-steroidal anti-inflammatory drug 490 
 491 
 492 
 493 
 494 
 495 
 496 
Variable Case  
N (%) 
Control  
N (%) 
Odds Ratio 95% 
Confidence 
Interval 
 p-value  
Walds 
test 
Likelihood 
ratio test 
Age  
 
Purebred status 
 
 
Goitre 
 
 
Heart auscultation 
abnormal 
 
NSAID1 
 
 
 
Hyperthyroidism 
 
Cardiomyopathy 
  
Days since last 
recorded 
anaesthetic 
Body weight (kg) 
< 9 years 
≥ 9 years 
Crossbred 
Purebred 
Unknown 
No 
Yes 
Not recorded 
No 
Yes 
Not Recorded 
No treatment recorded 
One off treatment recorded 
Repeated one off treatment recorded 
Long term treatment recorded 
No 
Yes 
No 
Yes 
0-179 days 
180 - 364 days 
No anaesthetic recorded within 1 year 
0 - 3 
3.01 - 3.5 
3.51 - 4.05 
4.07 - 4.78 
4.85 - 9.6 
No weight recorded 
58 (9.3) 
559 (89.4) 
530 (84.8) 
87 (13.9) 
8 (1.3) 
189 (30.2) 
61 (9.8) 
375 (60.0)  
307 (49.1) 
113 (18.1) 
205 (32.8) 
389 (62.2) 
142 (22.7) 
51 (8.2) 
43 (6.9) 
554 (88.6) 
71 (11.4) 
612 (97.9) 
13 (2.1) 
40 (6.4) 
20 (3.2) 
565 (90.4) 
51 (8.2) 
51 (8.2) 
53 (8.5) 
82 (13.1) 
81 (13.0) 
307 (49.1) 
89 (9.3) 
559 (89.4) 
553(88.5) 
59(9.4) 
13(2.1) 
33 (5.3) 
17(2.7) 
575(92.0) 
266 (45.6) 
57 (9.1) 
302 (48.3) 
350 (56.0) 
182 (29.1) 
79 (12.6) 
14 (2.2) 
615 (98.4) 
10 (1.6) 
606 (97.0) 
19 (3.0) 
71 (11.4) 
32 (5.12) 
522 (83.5) 
66 (10.6) 
58 (9.3) 
53 (8.5) 
31 (5.0) 
22 (3.5) 
395 (63.2) 
Reference 
0.75 
Reference 
1.72 
1.07 
Reference 
0.42 
0.13 
Reference 
1.64 
1.12 
Reference 
0.81 
0.7 
2.34 
Reference 
5.7 
Reference 
0.26 
Reference 
1.21 
2.07 
Reference 
1.03 
0.84 
0.36 
0.26 
0.7 
 
0.48 - 1.15 
 
1.15 - 2.58 
0.38 - 2.93 
 
0.21 - 0.85 
0.08 - 0.19 
 
1.06 - 2.54 
0.83 - 1.52 
 
0.60 - 1.11 
0.44 - 1.10 
1.12 - 4.88 
 
2.78 - 11.68 
 
0.10 - 0.65 
 
0.55 - 2.70 
1.28 - 3.36 
 
0.57 - 1.85 
0.46 - 1.54 
0.19 - 0.67 
0.13 - 0.51 
0.40 - 1.3 
 
0.18 
 
0.008 
 
 
0.02 
 
 
0.03 
 
 
0.19 
0.12 
0.02 
 
<0.001 
 
0.004 
 
0.63 
0.003 
 
0.92 
0.58 
0.001 
<0.001 
 
0.2 
 
0.03 
 
 
0.04 
 
 
0.08 
 
 
0.02 
 
 
 
<0.0001 
 
0.003 
 
0.005 
 
 
<0.0001 
Table 4: Multivariable Cox proportional hazards model for survival of at least one day following 497 
chronic kidney disease diagnosis in 533 cats attending primary-care practice in the UK from 1st 498 
January2012 to 31st December 2013 with follow up. Adjusted for vet group effects.  499 
Variable N Deaths Hazard 
Ratio 
95% 
Confidence 
Interval 
p-value 
Walds 
test 
Likelihood 
ratio test 
Purebred 
status 
 
Serum 
phosphate at 
diagnosis 
 
 
 
UPC1 
 
 
 
Renal diet 
 
Phosphate 
Binder 
IVFT2 
 
Cystitis 
 
Constipation 
 
 
 
 
Body weight 
(kg) 
 
 
 
 
 
 
0-400 days 
after 
diagnosis 
>400 days 
after diagnosis 
  
Crossbred 
Purebred 
Unknown 
<1.5mmol/l 
1.5mmol/l + 
Not recorded 
<1.5mmol/l 
1.5mmol/l + 
Not recorded 
0-0.2 
0.21-0.4 
>0.4 
Not recorded 
No 
Yes 
No 
Yes 
No 
Yes 
No 
Yes 
Before CKD 
diagnosis 
At CKD diagnosis 
After CKD diagnosis 
No constipation 
1.65 - 2.78 
2.8 - 3.23 
3.25 - 3.65 
3.67 - 4.3 
4.3 - 7.5 
No weight recorded 
446 
80 
7 
20 
68 
445 
12 
11 
159 
28 
19 
15 
471 
143 
390 
442 
91 
419 
114 
440 
93 
8 
 
3 
10 
512 
39 
37 
45 
43 
44 
325 
261 
40 
3 
4 
47 
190 
7 
6 
50 
6 
8 
11 
279 
94 
210 
257 
47 
222 
82 
262 
42 
8 
 
2 
5 
289 
31 
25 
30 
29 
25 
164 
Reference 
0.57 
0.3 
Reference 
5.78 
4.35 
Reference 
0.47 
0.45 
Reference 
3 
4.96 
2.77 
Reference 
0.58 
Reference 
0.68 
Reference 
1.97 
Reference 
0.69 
Reference 
 
0.35 
0.15 
0.23 
Reference 
0.87 
0.54 
0.47 
0.48 
1.4 
 
0.40 - 0.81 
0.09 - 0.96 
 
1.91 - 17.32 
1.49 - 12.71 
 
0.15 - 1.44 
0.20 - 1.01 
 
1.02 - 8.34 
1.78 - 13.81 
1.21 - 6.35 
 
0.45 - 0.75 
 
0.48 - 0.95 
 
1.48 - 2.62 
 
0.49 - 0.97 
 
 
0.07 - 1.78 
0.05 - 0.50 
0.11 - 0.51 
 
0.50 - 1.51 
0.32 - 0.92 
0.28 - 0.80 
0.27 - 0.83 
0.82 - 2.41 
 
0.002 
 
 
0.002 
 
 
0.2 
 
 
0.05 
0.002 
 
 
<0.001 
 
0.02 
 
<0.001 
 
0.02 
 
 
0.2 
0.002 
<0.001 
 
0.62 
0.02 
0.005 
0.009 
 
0.001 
 
 
<0.0001 
 
 
 
 
 
0.01 
 
 
 
0.0009 
 
0.02 
 
<0.0001 
 
0.02 
 
0.01 
 
 
 
 
0.0003 
 
 
 
 
 
1 Urine protein: creatinine ratio 2IVFT: Intravenous fluid therapy 500 
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